World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
121
Citations
52061
World Ranking
3620
National Ranking
99

Stanislas Pol publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stanislas Pol sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,033 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stanislas Pol D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stanislas Pol sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 121 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stanislas Pol is affiliated with Université Paris Cité in France and has contributed extensively to the field of medicine, with a particular focus on hepatology and epidemiology. Their research covers a range of topics related to liver diseases, viral hepatitis, and hepatocellular carcinoma.

The main fields of study for this scientist include:

  • Medicine

Within medicine, their subfields of study are:

  • Epidemiology
  • Hepatology
  • Oncology
  • Immunology
  • Infectious Diseases

The primary research topics addressed by Stanislas Pol span:

  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Alcohol Consumption and Health Effects
  • Hepatitis Viruses Studies and Epidemiology

Recent notable publications include:

  • "High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold" (2023), published in Diabetes Care
  • "Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis" (2021), published in Gut
  • "Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status" (2020), published in Journal of Hepatology
  • "Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area" (2020), published in JHEP Reports
  • "Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020" (2021), published in Journal of Hepatology

Frequent co-authors collaborating with Stanislas Pol include:

  • Fabrice Carrat
  • Victor de Lédinghen
  • Fabien Zoulim
  • Nathalie Ganne-Carrié
  • Marc Bourlière

The most common venues for their publications are:

  • Journal of Hepatology
  • JHEP Reports
  • Liver International
  • Alimentary Pharmacology & Therapeutics
  • SSRN Electronic Journal

Best Publications

  • FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

    Anaïs Vallet-Pichard;Anaïs Vallet-Pichard;Vincent Mallet;Vincent Mallet;Bertrand Nalpas;Bertrand Nalpas;Virginie Verkarre

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

    Fabrice Carrat;Firouzé Bani-Sadr;Stanislas Pol;Eric Rosenthal

  • Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

    P. André;F. Komurian-Pradel;S. Deforges;M. Perret

  • Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

    David Roth;David R. Nelson;Annette Bruchfeld;Annmarie Liapakis

  • Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

    Christian Bréchot;Valérie Thiers;Dina Kremsdorf;Bertrand Nalpas

  • Hepatitis C Virus Type 1b (II) Infection in France and Italy

    Jean-Baptiste Nousbaum;Stanislas Pol;Bertrand Nalpas;Paul Landais

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.

    Markus Cornberg;Homie A. Razavi;Alfredo Alberti;Enos Bernasconi

  • Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

    Pierre Nahon;Pierre Nahon;Valérie Bourcier;Richard Layese;Etienne Audureau

  • Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

    Nassim Kamar;Jacques Izopet;Simona Tripon;Michael Bismuth

  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

    Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey

  • Noninvasive In Vivo Liver Fibrosis Evaluation Using Supersonic Shear Imaging: A Clinical Study on 113 Hepatitis C Virus Patients

    Éric Bavu;Éric Bavu;Jean-Luc Gennisson;Mathieu Couade;Jeremy Bercoff

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

    Vincent Soriano;Massimo Puoti;Mark Sulkowski;Antonietta Cargnel

  • Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.

    Eva Herrmann;Victor de Lédinghen;Christophe Cassinotto;Winnie C.-W. Chu

  • All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

    Michael Peter Manns;Stanislas B Pol;Ira M Jacobson;Patrick M Marcellin

  • Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

    Edward Gane;Eric Lawitz;David Pugatch;Georgios Papatheodoridis

  • Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients

    Fabrice Carrat;Firouzé Bani-Sadr;Stanislas Pol;Eric Rosenthal

Frequent Co-Authors

Fabrice Carrat
Fabrice Carrat Sorbonne University
Patrice Cacoub
Patrice Cacoub Sorbonne University
Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Christophe Hézode
Christophe Hézode Université Paris Cité
Dominique Larrey
Dominique Larrey University of Montpellier
Jean-Pierre Bronowicki
Jean-Pierre Bronowicki University Hospital of Nancy
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées
Christian Bréchot
Christian Bréchot Institut Pasteur
Albert Tran
Albert Tran Inserm : Institut national de la santé et de la recherche médicale

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees can offer flexibility and affordability for students considering a healthcare career in the U.S. One popular direction is psychiatric mental health nursing. For those seeking a quick entry or advancement in this field, the shortest pmhnp program options allow licensed nurses to become psychiatric nurse practitioners faster than traditional paths.

Interested in healthcare leadership or administration? An online health management degree can be a stepping stone toward roles in hospitals, clinics, or public health organizations. For those looking to further maximize value, there are several most affordable online mha programs that combine quality education with lower tuition costs.

If advancing clinical expertise is your goal, the cheapest online dnp programs can help you achieve a Doctor of Nursing Practice degree without the financial burden often associated with advanced degrees. Each pathway offers unique career prospects, greater earning potential, and the convenience of studying from anywhere.

Best Scientists Citing Stanislas Pol

Trending Scientists

Recently Published Articles